<DOC>
	<DOCNO>NCT01753102</DOCNO>
	<brief_summary>Estradiol vaginal tablet tablet hydrate upon contact moisture , release 17ß-estradiol . The estradiol estradiol vaginal tablet chemically biologically identical endogenous human estradiol therefore classify human estrogen . The purpose study demonstrate clinical endpoint bioequivalence SPIL 's Estradiol vaginal tablet , 10mcg estradiol reference list drug ( Vagifem® ) approve marketed US .</brief_summary>
	<brief_title>Efficacy Safety Of Spil 's Estradiol Vaginal Tablet</brief_title>
	<detailed_description>Estradiol vaginal tablet indicate use treatment symptom atrophic vaginitis due estrogen deficiency . This randomized , observer blind , parallel group , active placebo control study test clinical endpoint bioequivalence test product ( Estradiol vaginal tablet , 10mcg Sun Pharmaceutical Industries Ltd. India ) relative reference ( Vagifem® , Estradiol vaginal tablet , 10mcg estradiol Novo Nordisk ) treatment vulvar vaginal atrophy . The patient administer one tablet intravaginally daily 14 day .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Postmenopausal woman At least one subjectselfassessed moderate severe symptom vulvar vaginal atrophy ≤ 5 % superficial cell vaginal smear cytology Vaginal pH &gt; 5.0 Consumption estrogen alone estrogen/progestin contain drug product . Allergy estradiol related product History breast cancer significant risk factor endometrial cancer Abnormal genital bleeding</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Estradiol</keyword>
	<keyword>Vulvar atrophy</keyword>
	<keyword>vaginal atrophy</keyword>
</DOC>